Clinical trials of betahistine hydrochloride in the treatment of Ménière's disease.
Thirty Ménière patients were treated with betahistine hydrochlorid for an average period of 17 months. The majority of them had been resistent to every previous treatment. The results of this new treatment were very gratifying with respect to the attacks of vertigo and the accompanying neuro-vegetative symptoms. The tinnitus aurium proved to be resistent, whereas the auditory acuity was significantly improved in 7 patients. Early treatment with this product at the first signs of Ménière's disease is very likely to hold up the progressive degradation of auditory acuity, during the further spontaneous evolution of the disease.
D001621:Betahistine / Q000627:therapeutic use*; D004341:Drug Evaluation; D006311:Hearing Disorders / Q000188:drug therapy; D006801:Humans; D008575:Meniere Disease / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D014012:Tinnitus / Q000188:drug therapy
D011725:Pyridines; D001621:Betahistine